Literature DB >> 27726316

Schedules of Controlled Substances: Placement of Three Synthetic Phenethylamines Into Schedule I. Final rule.zzm321990

.   

Abstract

With the issuance of this final rule, the Administrator of the Drug Enforcement Administration places three synthetic phenethylamines: 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5), 2-(4-chloro-2,5-dimethoxyphenyl)-N- (2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82), and 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B- NBOMe; 2C-B-NBOMe; 25B; Cimbi-36), including their optical, positional, and geometric isomers, salts and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible, into schedule I of the Controlled Substances Act. This scheduling action is pursuant to the Controlled Substances Act which requires that such actions be made on the record after opportunity for a hearing through formal rulemaking. This action continues the application of the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess), or propose to handle 25I-NBOMe, 25C-NBOMe, or 25B-NBOMe.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27726316

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  2 in total

1.  Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors.

Authors:  Amy J Eshleman; Katherine M Wolfrum; John F Reed; Sunyoung O Kim; Robert A Johnson; Aaron Janowsky
Journal:  Biochem Pharmacol       Date:  2018-09-25       Impact factor: 5.858

2.  Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats.

Authors:  Joshua S Elmore; Ann M Decker; Agnieszka Sulima; Kenner C Rice; John S Partilla; Bruce E Blough; Michael H Baumann
Journal:  Neuropharmacology       Date:  2018-03-01       Impact factor: 5.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.